These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11723420)

  • 21. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
    Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs for HIV infection.
    Med Lett Drugs Ther; 1997 Dec; 39(1015):111-6. PubMed ID: 9402928
    [No Abstract]   [Full Text] [Related]  

  • 24. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues.
    Claessens YE; Cariou A; Chiche JD; Dauriat G; Dhainaut JF
    AIDS; 2000 Mar; 14(4):472-3. PubMed ID: 10770558
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. When will once (-a day) be enough?
    Gandhi R; Flexner C
    Hopkins HIV Rep; 2000 May; 12(3):4, 10. PubMed ID: 12184233
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II/III Trials of Viracept start.
    AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361632
    [No Abstract]   [Full Text] [Related]  

  • 28. Contraindicated antiretroviral drug combinations.
    Macher A; Thomas D; Paul SM
    N J Med; 2003 Sep; 100(9 Suppl):41-3; quiz 73-4. PubMed ID: 14556602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delavirdine/protease inhibitor interactions.
    Gilden D
    GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Choosing which nuke to use first.
    AIDS Read; 2001 May; 11(5):248. PubMed ID: 11392690
    [No Abstract]   [Full Text] [Related]  

  • 31. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
    Moyle GJ; Wilkins E; Leen C; Cheesbrough A; Reynolds B; Gazzard BG
    AIDS; 2000 Jul; 14(10):1453-4. PubMed ID: 10930162
    [No Abstract]   [Full Text] [Related]  

  • 33. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
    J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
    Carr A
    Lancet; 2004 Apr; 363(9417):1248-50. PubMed ID: 15094265
    [No Abstract]   [Full Text] [Related]  

  • 37. [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():14-5. PubMed ID: 15011577
    [No Abstract]   [Full Text] [Related]  

  • 38. Raising levels of amprenavi.
    AIDS Patient Care STDS; 2000 Nov; 14(11):618. PubMed ID: 11155905
    [No Abstract]   [Full Text] [Related]  

  • 39. Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient.
    Tachikawa N; Yasuoka A; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):245-6. PubMed ID: 10738363
    [No Abstract]   [Full Text] [Related]  

  • 40. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.